The pathologic tumor stage after nRCT was ypT0 in 66 (15.6%), ypT1 in 29 (6.9%), ypT2 in 119 (28.1%), ypT3 in 189 (44.7%), and ypT4 in 20 patients (4.7%). This evidence concerns the gene RAB11B and neoplasm.